Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial

Table 1 Descriptive characteristics of octreotide, control and SSTR-negative group

	SSTR-negative group	Control group	Octreotide group	P
Number of patients	66	30	30		df	P
Age (yr)	69.4 ± 5.6	69.5 ± 5.6	69.4 ± 6.3	F = 0.009	125	> 0.05
Sex
Male	36 (55%)	22 (73%)	20 (67%)	χ2 = 3.45	2	> 0.05
Etiology				χ2 = 9.133	4	> 0.05
HBV	38 (58%)	10 (33%)	10 (33%)
HCV	26 (39%)	17 (57%)	19 (63%)
HBV + HVC	2 (3%)	3 (10%)	1 (3%)
Morphology				χ2 = 0.842	4	> 0.05
Multi nodular	13 (20%)	6 (20%)	7 (23%)
Massive	45 (68%)	20 (67%)	21 (70%)
Diffuse	8 (12%)	4 (13%)	2 (7%)
AFP	3208 ± 4500	3096 ± 4500	2714 ± 5049	F = 0.057	125	> 0.05
Metastases	8 (12%)	7 (23%)	4 (13%)	χ2 = 2.118	2	> 0.05
Cirrhosis
Stage B	32 (49%)	19 (63%)	15 (50%)	χ2 = 1.91	2	> 0.05
BCLC
Stage C	56 (85%)	25 (83%)	25 (83%)	χ2 = 0.054	2	> 0.05

Table 2 Follow up of patients

	SSTR-negativegroup	Controlgroup	Octreotidegroup	P
Number of events within 6 mo	25 (38%)	12 (40%)	6 (13%)	0.171
Number of events within 12 mo	65 (99%)	29 (97%)	21 (70%)	< 0.001
Number of events at the end of follow up	66 (100%)	30 (100%)	29 (97%)	1.000
Overall survival time (wk)	28; 21 to 33	28; 19 to 34	49; 28 to 72	< 0.0001